Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: An electronic device is provided. The electronic device includes a body member defining a groove, a decorative member may be integrally insert-molded to the body member, a printed circuit board facing the body member and a lamp electrically mounted to the printed circuit board. The lamp is used to illuminate the decorative member.

Abstract: The invention discloses a tissue engineering graft, comprising:(a) pharmaceutically-acceptable biodegradable material; and (b) seed cells, which can be inoculated on the described biodegradable material and are selected from:(i) fibroblasts; (ii) adipose derived cells, or (iii) mixture of dermal fibroblasts and ASCs according to the ratio of 1:10000-10000:1. The graft can be prepared by mixing of seed cell and pharmaceutically-acceptable biodegradable material, obtaining a construct of seed cells and pharmaceutically-acceptable biodegradable material, then culturing the construct in a bioreactor in vitro. The graft can be used for repairing the defect of tendon tissues.

Abstract: The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and/or ZB-1 activity, expression, and/or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides.

Abstract: A film comprises a base layer, a first patterned layer and a second patterned layer. The base layer includes a first surface and a second surface opposite to the first surface. The first patterned layer is laminated with the base layer partially over the first surface of the base layer. The first patterned layer is belt-shaped and includes a plurality of spaced first strip patterns, such that a first interval space is defined between adjacent two first strip pattern. The second patterned layer is laminated with the base layer partially over the second surface of the base layer. The second patterned layer being belt-shaped and includes a plurality of spaced second strip patterns corresponding to the first strip patterns. The second strip patterns are partially overlapped with corresponding first strip patterns and the rest of the second strip patterns are partially overlapped with corresponding first interval spaces.

Abstract: A shell for a portable electronic device includes a transparent base shell, a light-transmittable layer, a opaque layer, and a pattern layer. The transparent base shell includes an exterior surface and an interior surface opposite to the exterior surface. The light-transmittable layer is directly formed on the interior surface and only allows a portion of light to pass there through. The opaque layer is directly formed on the light-transmittable layer. The light-transmittable layer is located between the base shell and the intermediate layer. The pattern layer covers over and around the intermediate layer to form a pattern section inside the intermediate layer. The pattern section and the pattern layer are light-transmittable by a predetermined color.

Abstract: An electronic device is provided. The electronic device includes a body member defining a groove, a decorative member may be integrally insert-molded to the body member, a printed circuit board facing the body member and a lamp electrically mounted to the printed circuit board. The lamp is used to illuminate the decorative member.

Abstract: A housing includes a base layer, a cover layer and an embedding member, the base layer is formed in a first molding, the cover layer is formed in a second molding, the embedding member is between the base layer and the cover layer, the base layer has locking members formed thereon in the first molding, the embedding member is firmly latched with the locking members in the second molding. A method for fabricating the housing is also described.